{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:06:31Z","timestamp":1790622391115,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Learning and Memory"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.nlm.2016.06.020","type":"journal-article","created":{"date-parts":[[2016,6,27]],"date-time":"2016-06-27T09:34:20Z","timestamp":1467020060000},"page":"100-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["The selective 5-HT 6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment"],"prefix":"10.1016","volume":"133","author":[{"given":"N.M.W.J.","family":"de Bruin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"van Loevezijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.M.","family":"Wicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"de Haan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Venhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.M.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"de Groote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.W.","family":"van der Neut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Prickaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Andriambeloson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van Drimmelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"van der Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.G.","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.nlm.2016.06.020_b0005","first-page":"471","article-title":"Intrahippocampal injections of the beta-amyloid 1\u201328 fragment induces behavioral deficits in rats","volume":"19","author":"Alvarez","year":"1997","journal-title":"Methods and Findings in Experimental and Clinical Pharmacology"},{"key":"10.1016\/j.nlm.2016.06.020_b0010","series-title":"International review of neurobiology: Pharmacology of 5-HT6 receptors, part II","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/B978-0-12-385902-0.00006-1","article-title":"5-HT6 Receptor ligands and their antipsychotic potential","author":"Arnt","year":"2011"},{"key":"10.1016\/j.nlm.2016.06.020_b0015","author":"Axovant Sciences Inc"},{"key":"10.1016\/j.nlm.2016.06.020_b0020","unstructured":"Axovant\u2019s RVT-101 Phase 2b Completer Analysis Demonstrates Statistically Significant Benefits in Cognition and Function Through 48 Weeks. (2015). In Alzheimer\u2019s association international conference. Retrieved from <http:\/\/www.prnewswire.com\/news-releases\/axovants-rvt-101-phase-2b-completer-analysis-demonstrates-statistically-significant-benefits-in-cognition-and-function-through-48-weeks-300116866.html>."},{"issue":"7","key":"10.1016\/j.nlm.2016.06.020_b0025","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1073\/pnas.92.7.2785","article-title":"Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains","volume":"92","author":"Barbeau","year":"1995","journal-title":"PNAS"},{"key":"10.1016\/j.nlm.2016.06.020_b0030","doi-asserted-by":"crossref","DOI":"10.1021\/jm5003952","article-title":"Serotonin 5-HT 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer\u2019s disease","author":"Benham\u00fa","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pscychresns.2007.12.012","article-title":"Episodic memory in schizophrenia: The influence of strategy use on behavior and brain activation","volume":"164","author":"Bonner-Jackson","year":"2008","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.nlm.2016.06.020_b0040","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4419-1170-4_19","article-title":"NCAM in neuropsychiatric and neurodegenerative disorders","volume":"663","author":"Brennaman","year":"2010","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1016\/j.nlm.2016.06.020_b0045","unstructured":"Callahan, P. M., Ilch, C. P., Rowe, W. B., & Tehim, A. (2004). Characterization of the selective 5-HT6 receptor antagonist SB 271046 in behavioral models of cognition. Society for Neuroscience \u2013 Abstract Archive: 2000-2005, 776.19."},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1023\/A:1023870821631","article-title":"Verbal declarative memory dysfunction in schizophrenia: From clinical assessment to genetics and brain mechanisms","volume":"13","author":"Cirillo","year":"2003","journal-title":"Neuropsychology Review"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","article-title":"5-HT(6) receptor and cognition","volume":"11","author":"Codony","year":"2011","journal-title":"Current Opinion in Pharmacology"},{"issue":"39","key":"10.1016\/j.nlm.2016.06.020_b0060","doi-asserted-by":"crossref","first-page":"8898","DOI":"10.1523\/JNEUROSCI.2693-05.2005","article-title":"Acute-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer\u2019s disease","volume":"25","author":"Comery","year":"2005","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.nlm.2016.06.020_b0065","unstructured":"Comery, T. A., & Schechter, L. E. (2007). Method for the treatment of cognitive dysfunction."},{"issue":"8","key":"10.1016\/j.nlm.2016.06.020_b0070","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1136\/jnnp.2006.095414","article-title":"A review of screening tests for cognitive impairment","volume":"78","author":"Cullen","year":"2007","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0075","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1358\/dof.2005.030.05.907630","article-title":"Drug discovery targets: 5-HT6, receptor","volume":"30","author":"Davies","year":"2005","journal-title":"Drugs of the Future"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0080","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0893-133X(01)00265-2","article-title":"The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus","volume":"25","author":"Dawson","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0085","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.physbeh.2006.08.009","article-title":"Attentional performance of (C57BL\/6Jx129Sv)F2 mice in the five-choice serial reaction time task","volume":"89","author":"de Bruin","year":"2006","journal-title":"Physiology & Behavior"},{"issue":"26","key":"10.1016\/j.nlm.2016.06.020_b0090","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.2174\/1381612821666150605112105","article-title":"5-HT6 Receptor antagonists: Potential efficacy for the treatment of cognitive impairment in schizophrenia","volume":"21","author":"de Bruin","year":"2015","journal-title":"Current Pharmaceutical Design"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pbb.2006.08.007","article-title":"Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval","volume":"85","author":"de Bruin","year":"2006","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0100","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.nlm.2010.01.010","article-title":"SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents","volume":"93","author":"de Bruin","year":"2010","journal-title":"Neurobiology of Learning and Memory"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0105","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","article-title":"Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats","volume":"96","author":"de Bruin","year":"2011","journal-title":"Neurobiology of Learning and Memory"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1037\/h0045446","article-title":"Spontaneous alternation behavior","volume":"55","author":"Dember","year":"1958","journal-title":"Psychological Bulletin"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbr.2010.03.017","article-title":"Emotion and episodic memory in neuropsychiatric disorders","volume":"215","author":"Dere","year":"2010","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0120","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behavioural Brain Research"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.neuropharm.2012.05.042","article-title":"Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder","volume":"63","author":"Foley","year":"2012","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.nlm.2016.06.020_b0130","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.neuropharm.2008.03.012","article-title":"The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats","volume":"54","author":"Foley","year":"2008","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.nlm.2016.06.020_b0135","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1038\/npp.2009.89","article-title":"H3 receptor antagonism enhances NCAM PSA-mediated plasticity and improves memory consolidation in odor discrimination and delayed match-to-position paradigms","volume":"34","author":"Foley","year":"2009","journal-title":"Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0140","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuropharm.2008.06.061","article-title":"An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function","volume":"55","author":"Fone","year":"2008","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0145","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.neubiorev.2008.03.003","article-title":"Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders","volume":"32","author":"Fone","year":"2008","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"7","key":"10.1016\/j.nlm.2016.06.020_b0150","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1586\/ern.09.51","article-title":"The serotonin 5-HT6 receptor: A viable drug target for treating cognitive deficits in Alzheimer\u2019s disease","volume":"9","author":"Geldenhuys","year":"2009","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0166-4328(97)00214-3","article-title":"A new continuous alternation task in T-maze detects hippocampal dysfunction in mice. A strain comparison and lesion study","volume":"95","author":"Gerlai","year":"1998","journal-title":"Behavioural Brain Research"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0160","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0006-3223(93)90180-L","article-title":"Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia","volume":"34","author":"Geyer","year":"1993","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0165","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nature Biotechnology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0892-0362(99)00083-5","article-title":"Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism","volume":"22","author":"Ingram","year":"2000","journal-title":"Neurotoxicology and Teratology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0175","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acs.molpharmaceut.5b00830","article-title":"AVN-211, novel and highly selective 5-HT 6 receptor small molecule antagonist, for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Ivachtchenko","year":"2016","journal-title":"Molecular Pharmaceutics"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0180","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","article-title":"The neuropsychopharmacology of phencyclidine from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia","volume":"20","author":"Jentsch","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.nlm.2016.06.020_b0185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0893-133X(97)00034-1","article-title":"Subchronic phencyclidine administration dopamine utilization reduces mesoprefrontal and impairs prefrontal cortical-dependent cognition in the rat","volume":"17","author":"Jentsch","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0190","first-page":"642","article-title":"5-HT6 receptor antagonists: Prospects for the treatment of cognitive disorders including dementia","volume":"11","author":"Johnson","year":"2008","journal-title":"Current Opinion in Drug Discovery & Development"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0195","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1476-5381.2011.01386.x","article-title":"Animal models of schizophrenia","volume":"164","author":"Jones","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.nlm.2016.06.020_b0200","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT(1A), 5-HT(4) and 5-HT(6) receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/syn.10288","article-title":"5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex","volume":"51","author":"Lacroix","year":"2004","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","article-title":"Effects of ketamine in normal and schizophrenic volunteers","volume":"25","author":"Lahti","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0215","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbr.2008.03.017","article-title":"Effects of the genetic background on cognitive performances of TG2576 mice","volume":"191","author":"Lassalle","year":"2008","journal-title":"Behavioural Brain Research"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0220","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF02245565","article-title":"CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats","volume":"115","author":"Lemaire","year":"1994","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.nlm.2016.06.020_b0225","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/sj.npp.1300777","article-title":"The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat","volume":"30","author":"Lieben","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"21","key":"10.1016\/j.nlm.2016.06.020_b0230","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.1021\/jm1007825","article-title":"5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists","volume":"53","author":"Liu","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.nlm.2016.06.020_b0235","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00213-007-0934-5","article-title":"Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: Implication of the frontal cortex","volume":"196","author":"Loiseau","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nlm.2016.06.020_b0240","unstructured":"Lundbeck A\/S, H. (2010). First quarter report 2010. Corporate Release No 403."},{"key":"10.1016\/j.nlm.2016.06.020_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1567210200438162050","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer\u2019s disease","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Current Alzheimer Research"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0250","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjp.2008.281","article-title":"Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat","volume":"155","author":"Marcos","year":"2008","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.neuropharm.2011.03.003","article-title":"Influence of social isolation in the rat on serotonergic function and memory \u2013 Relevance to models of schizophrenia and the role of 5-HT6 receptors","volume":"61","author":"Marsden","year":"2011","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0260","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2174\/156720508785908874","article-title":"Relevance of Abeta 1\u201342 intrahippocampal injection as an animal model of inflamed Alzheimers disease brain","volume":"5","author":"McLarnon","year":"2008","journal-title":"Current Alzheimer Research"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0265","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.neuropharm.2005.10.002","article-title":"BGC20-761, a novel tryptamine analog, enhances memory consolidation and reverses scopolamine-induced memory deficit in social and visuospatial memory tasks through a 5-HT6 receptor-mediated mechanism","volume":"50","author":"Mitchell","year":"2006","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0270","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.pharmthera.2005.05.001","article-title":"5-HT6 receptors: A novel target for cognitive enhancement","volume":"108","author":"Mitchell","year":"2005","journal-title":"Pharmacology & Therapeutics"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0165-0173(92)90017-G","article-title":"Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model","volume":"17","author":"Molchan","year":"1992","journal-title":"Brain Research Reviews"},{"issue":"04","key":"10.1016\/j.nlm.2016.06.020_b0280","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1017\/S1092852913000394","article-title":"Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: Pilot study","volume":"19","author":"Morozova","year":"2014","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.nlm.2016.06.020_b0285","first-page":"S54","article-title":"A 14 day, dose escalation, double blind, randomized, placebo-controlled study of SGS518 in adult patients with schizophrenia","volume":"30","author":"Neale","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","article-title":"Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism","volume":"128","author":"Neill","year":"2010","journal-title":"Pharmacology & Therapeutics"},{"issue":"5 Part 2","key":"10.1016\/j.nlm.2016.06.020_b0295","doi-asserted-by":"crossref","first-page":"34R","DOI":"10.1203\/PDR.0b013e318212b80f","article-title":"Modeling autistic features in animals","volume":"69","author":"Patterson","year":"2011","journal-title":"Pediatric Research"},{"key":"10.1016\/j.nlm.2016.06.020_b0300","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nrd3649","article-title":"Advancing schizophrenia drug discovery: Optimizing rodent models to bridge the translational gap","volume":"11","author":"Pratt","year":"2012","journal-title":"Nature Reviews Drug Discovery"},{"issue":"S1","key":"10.1016\/j.nlm.2016.06.020_b0305","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1038\/bjp.2008.24","article-title":"Modelling prefrontal cortex deficits in schizophrenia: Implications for treatment","volume":"153","author":"Pratt","year":"2009","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0310","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuint.2004.03.022","article-title":"Phosphodiesterase type 5 inhibition improves early memory consolidation of object information","volume":"45","author":"Prickaerts","year":"2004","journal-title":"Neurochemistry International"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0315","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156802610790411036","article-title":"5-HT6 receptor antagonists as potential therapeutics for cognitive impairment","volume":"10","author":"Rosse","year":"2010","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0320","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.npp.1301503","article-title":"Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466","volume":"33","author":"Schechter","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.npp.1300518","article-title":"Behavioral alterations in rats prenatally exposed to valproic acid: Animal model of autism","volume":"30","author":"Schneider","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0330","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.psyneuen.2008.02.011","article-title":"Gender-specific behavioral and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid","volume":"33","author":"Schneider","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0335","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbr.2009.02.007","article-title":"Evaluation of NMDA receptor models of schizophrenia: Divergences in the behavioral effects of sub-chronic PCP and MK-801","volume":"204","author":"Seillier","year":"2009","journal-title":"Behavioural Brain Research"},{"issue":"1\u20132","key":"10.1016\/j.nlm.2016.06.020_b0340","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbr.2003.08.004","article-title":"The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse","volume":"151","author":"Spowart-Manning","year":"2004","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/j.nlm.2016.06.020_b0345","first-page":"7","article-title":"Serotonin 5-HT6 receptor: A potential target for cognition","volume":"1","author":"Sulbha","year":"2010","journal-title":"International Journal of Pharmacy"},{"issue":"3\u20135","key":"10.1016\/j.nlm.2016.06.020_b0350","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0278-5846(86)90030-8","article-title":"Pharmacologic modelling of Alzheimer\u2019s disease","volume":"10","author":"Sunderland","year":"1986","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.nlm.2016.06.020_b0355","unstructured":"Upton, N., Chuang, T. T., Hunter, A. J., & Virley, D. J. (2008). 5-HT 6 receptor antagonists as novel cognitive enhancing agents for Alzheimer\u2019s disease (Vol. 5(July), pp. 458\u2013469)."},{"key":"10.1016\/j.nlm.2016.06.020_b0360","doi-asserted-by":"crossref","first-page":"7030","DOI":"10.1021\/jm200466r","article-title":"N-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) Antagonists with unique structural features","volume":"54","author":"van Loevezijn","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.nlm.2016.06.020_b0365","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bmcl.2016.02.001","article-title":"Optimization of N\u2032-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket","volume":"26","author":"van Loevezijn","year":"2016","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"April","key":"10.1016\/j.nlm.2016.06.020_b0370","first-page":"88","article-title":"Using mice to model Alzheimer\u2019s dementia: An overview of the clinical disease and the preclinical behavioral changes in 10 mouse models","volume":"5","author":"Webster","year":"2014","journal-title":"Frontiers in Genetics"},{"issue":"5","key":"10.1016\/j.nlm.2016.06.020_b0375","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/archneur.1992.00530290030008","article-title":"Detection and staging of dementia in Alzheimer\u2019s disease","volume":"49","author":"Welsh","year":"1992","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1016\/j.nlm.2016.06.020_b0380","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.neuroscience.2009.07.061","article-title":"Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus","volume":"164","author":"West","year":"2009","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.nlm.2016.06.020_b0385","doi-asserted-by":"crossref","first-page":"P529","DOI":"10.1016\/j.jalz.2013.04.267","article-title":"A clinical phase II study of Lu AE58054 added to stable donepezil treatment in patients with moderate Alzheimer\u2019s disease","volume":"9","author":"Wilkinson","year":"2013","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"11","key":"10.1016\/j.nlm.2016.06.020_b0390","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): A randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"The Lancet Neurology"},{"issue":"3","key":"10.1016\/j.nlm.2016.06.020_b0395","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1533317509332094","article-title":"Donepezil in patients with severe Alzheimer\u2019s disease","volume":"24","author":"Winblad","year":"2009","journal-title":"American Journal of Alzheimer\u2019s Disease & Other Dementias"}],"container-title":["Neurobiology of Learning and Memory"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074742716300946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074742716300946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T19:25:32Z","timestamp":1536607532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074742716300946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":79,"alternative-id":["S1074742716300946"],"URL":"https:\/\/doi.org\/10.1016\/j.nlm.2016.06.020","relation":{},"ISSN":["1074-7427"],"issn-type":[{"value":"1074-7427","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The selective 5-HT6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Learning and Memory","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nlm.2016.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}